<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
TARO PHARMACEUTICAL INDUSTRIES LTD.
--------------------------------------------------------------------------------
(Name of Issuer)
Ordinary Shares, NIS 0.0001 nominal par value per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
M8737E108
---------
(CUSIP Number)
September 21, 2000
------------------
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6 pages
<PAGE>
-------------------------------- -----------------------------------
CUSIP No. M8737E108 13G Page 2 of 6 Pages
---------------------- ----- -----
-------------------------------- ------------------------------------
---------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Cumberland Associates LLC
---------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [X]
---------- ---------------------------------------------------------------------
SEC USE ONLY
3
---------- ---------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
-------------------- ------ ----------------------------------------------------
5 SOLE VOTING POWER
504,100
------ ----------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 46,400
OWNED BY
------ ----------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 504,100
WITH
------ ----------------------------------------------------
8 SHARED DISPOSITIVE POWER
46,400
---------- ---------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
550,500
---------- ---------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES [ ]
---------- ---------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.1%
---------- ---------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
OO, IA
---------- ---------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
Page 2 of 6 pages
<PAGE>
Item 1(a) Name of Issuer:
--------------
Taro Pharmaceutical Industries Ltd. (the "Issuer")
Item 1(b) Address of Issuer's Principal Executive Offices:
-----------------------------------------------
32 Maskit Street
Beit Merkazim
Herzlia Pituach 46120
Israel
Item 2(a) Name of Person Filing:
----------------------
This statement is being filed by Cumberland Associates LLC.
Cumberland Associates LLC is a limited liability company
organized under the laws of the State of New York, and is
engaged in the business of managing, on a discretionary
basis, ten securities accounts (the "Accounts"), the
principal one of which is Cumberland Partners. Gary Tynes,
Oscar S. Schafer, Bruce G. Wilcox, Glenn Krevlin, Andrew
Wallach and Dipak M. Patel are the members (the "Members")
of Cumberland Associates LLC.
Item 2(b) Address of Principal Business Office:
-------------------------------------
The address of the principal business and office of
Cumberland Associates LLC and each of the Members is 1114
Avenue of the Americas, New York, New York 10036.
Item 2(c) Citizenship:
------------
Cumberland Associates LLC is a New York limited liability
company. Each of the Members is a citizen of the United
States.
Item 2(d) Title of Class of Securities:
-----------------------------
Ordinar Shares, NIS 0.0001 nominal par value per share (the
"Shares")
Item 2(e) CUSIP Number:
-------------
M8737E108
---------
Item 3 Not Applicable
Item 4. Ownership:
----------
Page 3 of 6 pages
<PAGE>
Item 4(a) Amount Beneficially Owned:
--------------------------
As of the date hereof, Cumberland Associates LLC may be
deemed to be the beneficial owner of 550,500 Shares.
Item 4(b) Percent of Class:
-----------------
The number of Shares of which Cumberland Associates LLC may
be deemed to be the beneficial owner constitutes
approximately 5.1% of the total number of Shares
outstanding.
Item 4(c) Number of shares as to which such person has:
---------------------------------------------
(i) Sole power to vote or to direct the vote: 504,100
(ii) Shared power to vote or to direct the vote: 46,400
(iii) Sole power to dispose or to direct the disposition
of: 504,100
(iv) Shared power to dispose or to direct the
disposition of: 46,400
Item 5 Ownership of Five Percent or Less of a Class:
---------------------------------------------
If this statement is being filed to report the fact that as
of the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following.[ ]
Item 6 Ownership of More than Five Percent on Behalf of Another
Person:
--------------------------------------------------------
The beneficial owners of the Accounts have the right to
participate in the receipt of dividends from, or proceeds
from the sale of, the Shares held for each Account in
accordance with their ownership interests in each such
Account.
Item 7 Identification and Classification of the
Subsidiary Which Acquired the Security Being
Reported on By the Parent Holding Company:
--------------------------------------------
Not Applicable
Page 4 of 6 pages
<PAGE>
Item 8 Identification and Classification of Members
of the Group:
---------------------------------------------
Not Applicable
Item 9 Notice of Dissolution of Group:
-------------------------------
Not Applicable
Item 10 Certification:
--------------
By signing below the signatory certifies that, to the best of his knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the Issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
Page 5 of 6 pages
<PAGE>
SIGNATURE
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: October 2, 2000
CUMBERLAND ASSOCIATES LLC
By: /s/ Oscar S. Schafer
---------------------------------
Name: Oscar S. Schafer
Title: Member
Page 6 of 6 pages
